- Home
- ONCO vs THAR Comparison
ONCO vs THAR Comparison
Compare ONCO & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONCO
- THAR
- Stock Information
- Founded
- ONCO 2018
- THAR 2017
- Country
- ONCO United States
- THAR United States
- Employees
- ONCO N/A
- THAR N/A
- Industry
- ONCO Biotechnology: Pharmaceutical Preparations
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- ONCO Health Care
- THAR Health Care
- Exchange
- ONCO Nasdaq
- THAR Nasdaq
- Market Cap
- ONCO 3.3M
- THAR 2.8M
- IPO Year
- ONCO 2022
- THAR 2022
- Fundamental
- Price
- ONCO $0.43
- THAR $2.13
- Analyst Decision
- ONCO
- THAR
- Analyst Count
- ONCO 0
- THAR 0
- Target Price
- ONCO N/A
- THAR N/A
- AVG Volume (30 Days)
- ONCO 282.9K
- THAR 232.7K
- Earning Date
- ONCO 12-24-2024
- THAR 11-07-2024
- Dividend Yield
- ONCO N/A
- THAR N/A
- EPS Growth
- ONCO N/A
- THAR N/A
- EPS
- ONCO N/A
- THAR N/A
- Revenue
- ONCO $1,870,605.00
- THAR N/A
- Revenue This Year
- ONCO N/A
- THAR N/A
- Revenue Next Year
- ONCO N/A
- THAR N/A
- P/E Ratio
- ONCO N/A
- THAR N/A
- Revenue Growth
- ONCO N/A
- THAR N/A
- 52 Week Low
- ONCO $0.37
- THAR $1.84
- 52 Week High
- ONCO $21.40
- THAR $8.55
- Technical
- Relative Strength Index (RSI)
- ONCO 22.61
- THAR 46.63
- Support Level
- ONCO $0.37
- THAR $2.09
- Resistance Level
- ONCO $0.47
- THAR $2.27
- Average True Range (ATR)
- ONCO 0.10
- THAR 0.17
- MACD
- ONCO 0.10
- THAR -0.00
- Stochastic Oscillator
- ONCO 15.28
- THAR 34.04
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.